PharmaTutor (January- 2014)
ISSN: 2347 - 7881
Received On: 11/01/2014; Accepted On: 13/01/2014; Published On: 15/01/2014
About Authors: Amit Gangwal
Department of pharmacognosy
Smriti college of pharmaceutical education, Indore
gangwal.amit@gmail.com
INTRODUCTION: At least one article is seen in newspaper on obesity on daily basis; no other disease is searched (and articles are read on) as frequently as obesity. Such is the menace of obesity that even fast food giant McDonald's has put an advice in few of its offices “not to eat too much fast-food”. Obesity is defined as BMI (body mass index) 30kg\m2 or more. A person with a BMI between 25 and 29.9 are considered over weight but not obese. BMI is a simple index of weight-for-height that is commonly used to classify overweight and obesity in humans. It is also defined as a person’s weight in kilograms divided by the square of his height in meters (kg\m2). As per world health organization (WHO), BMI greater than or equal to 25 is overweight and BMI greater than or equal to 30 is obese. Obesity is a foremost health problem not only in developed nations but also in developing countries. It increases the risk of other diseases like diabetes, cardiovascular ailments, fatty liver and some forms of cancer. Obesity is now so common in various geographies that it is beginning to replace conditions arising from malnutrition and infectious diseases as the most significant contributor to ill health. Obesity is measured using BMI and further evaluated in terms of fat distribution via the waist–hip ratio and total cardiovascular risk factors. BMI is closely related to both percentage body fat and total body fat. The global epidemic of obesity results from an amalgamation of such factors as genetic susceptibility, increased availability of high-energy foods and diminished need of physical activity in prevailing situation in modern society.
How to cite this article: A Gangwal, Next Lipitor® will also be from metabolic therapy, PharmaTutor, 2014, 2(1), 8-12